An analytical TD-GC-MS method was developed and used for the assessment of volatile organic compounds (VOCs) released from the blood plasma of dogs with/without cancer. VOCs released from 40 samples of diseased blood and 10 control samples were compared in order to examine the difference between both sample groups that were showing qualitatively similar results independent from the disease’s presence. However, mild disturbances in the spectra of dogs with cancer in comparison with the control group were observed, and six peaks (tentatively identified by comparison with mass spectral library as hexanal, octanal, toluene, 2-butanone, 1-octen-3-ol and pyrrole) revealed statistically significant differences between both sample groups, thereby suggesting that these compounds are potential biomarkers that can be used for cancer diagnosis based on the blood plasma TD-GC-MS analysis. Statistical comparison with the application of principal component analysis (PCA) provided accurate discrimination between the cancer and control groups, thus demonstrating stronger biochemical perturbations in blood plasma when cancer is present.
References
[1]
Rosenthal, M.D.; Glew, R.H. Medical Biochemistry: Human Metabolism in Health and Disease; John Wiley & Sons: Hoboken, NJ, USA, 2009; pp. 1–3.
[2]
Jellum, E.; Stokke, O.; Eldjarn, L. Application of gas chromatography, mass spectrometry, and computer methods in clinical biochemistry. Anal. Chem. 1973, 45, 1099–1106, doi:10.1021/ac60329a036.
[3]
Ma, S.; Turino, G.M.; Lin, Y.Y. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J. Chromatogr. B 2011, 879, 1893–1898, doi:10.1016/j.jchromb.2011.05.011.
[4]
Duffy, M.J. Clinical uses of tumor markers: A critical review. Crit. Rev. Clin. Lab. Sci. 2001, 38, 225–262, doi:10.1080/20014091084218.
[5]
Ilic, D.; O’Connor, D.; Green, S.; Wilt, T.J. Screening for prostate cancer: An updated Cochrane systematic review. BJU Int. 2011, 107, 882–891, doi:10.1111/j.1464-410X.2010.10032.x.
[6]
Wu, H.; Xue, R.; Lu, C.; Deng, C.; Liu, T.; Zeng, H.; Wang, Q.; Shen, X. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J. Chromatogr. B 2009, 877, 3111–3117, doi:10.1016/j.jchromb.2009.07.039.
[7]
Amann, A.; Poupart, G.; Telser, S.; Ledochowski, M.; Schmid, A.; Mechtcheriakov, S. Applications of breath gas analysis in medicine. Int. J. Mass Spectrom. 2004, 239, 227–233, doi:10.1016/j.ijms.2004.08.010.
Bajtarevic, A.; Ager, C.; Pienz, M.; Klieber, M.; Schwarz, K.; Ligor, M.; Ligor, T.; Filipiak, W.; Denz, H.; Fiegl, M.; et al. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009, 9, doi:10.1186/1471-2407-9-348.
[10]
Horváth, I.; Hunt, J.; Barnes, P.J.; Alving, K.; Antczak, A.; Baraldi, E.; Becher, G.; van Beurden, W.J.C.; Corradi, M.; Dekhuijzen, R.; et al. Exhaled breath condensate: Methodological recommendations and unresolved questions. Eur. Resp. J. 2005, 26, 523–548, doi:10.1183/09031936.05.00029705.
[11]
Banday, K.M.; Pasikanti, K.K.; Chan, E.C.Y.; Singla, R.; Rao, K.V.S.; Chauhan, V.S.; Nanda, R.K. Use of urine volatile organic compounds to discriminate tuberculosis patients from healthy subjects. Anal. Chem. 2011, 83, 5526–5534, doi:10.1021/ac200265g.
[12]
Dubbelman, A.C.; Tibben, M.; Rosing, H.; Gebretensae, A.; Nan, L.; Gorman, S.H.; Robertson, P.; Schellens, J.H.M.; Beijnen, J.H. Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. J. Chromatogr. B 2012, 893–894, 92–100.
[13]
Deng, C.; Li, N.; Zhang, X. Development of headspace solid-phase microextraction with on-fiber derivatization for determination of hexanal and heptanal in human blood. J. Chromatogr. B 2004, 813, 47–52, doi:10.1016/j.jchromb.2004.09.007.
[14]
Deng, C.; Zhang, X.; Li, N. Investigation of volatile biomarkers in lung cancer blood using solid-phase microextraction and capillary gas chromatography-mass spectrometry. J. Chromatogr. B 2004, 808, 269–277, doi:10.1016/j.jchromb.2004.05.015.
[15]
Sponring, A.; Filipiak, W.; Mikoviny, T.; Ager, C.; Schubert, J.; Miekisch, W.; Amann, A.; Troppmair, J. Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res. 2009, 29, 419–426.
[16]
Filipiak, W.; Sponring, A.; Mikoviny, T.; Ager, C.; Schubert, J.; Miekisch, W.; Amann, A.; Troppmair, J. Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer Cell Int. 2008, 8, doi:10.1186/1475-2867-8-17.
[17]
Sponring, A.; Filipiak, W.; Ager, C.; Schubert, J.; Miekisch, W.; Amann, A.; Troppmair, J. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Canc. Biomarkers 2010, 7, 153–161.
[18]
Fisch？der, G.; R？der-Stolinski, C.; Wichmann, G.; Nieber, K.; Lehmann, I. Release of MCP-1 and IL-8 from lung epithelial cells exposed to volatile organic compounds. Toxicol. In Vitro 2008, 22, 359–366, doi:10.1016/j.tiv.2007.09.015.
[19]
Laturnus, F. Release of volatile halogenated organic compounds by unialgal cultures of polar macroalgae. Chemosphere 1995, 31, 3387–3395, doi:10.1016/0045-6535(95)00190-J.
[20]
Allardyce, R.A.; Langford, V.S.; Hill, A.L.; Murdoch, D.R. Detection of volatile metabolites produced by bacterial growth in blood culture media by selected ion flow tube mass spectrometry (SIFT-MS). J. Microbiol. Meth. 2006, 65, 361–365, doi:10.1016/j.mimet.2005.09.003.
[21]
Theodoridis, G.; Gika, H.G.; Wilson, I.D. LC-MS-based methodology for global metabolite profiling in metabonomics/metabolomics. TrAC Trends Anal. Chem. 2008, 27, 251–260, doi:10.1016/j.trac.2008.01.008.
[22]
Wilson, I.D.; Plumb, R.; Granger, J.; Major, H.; Williams, R.; Lenz, E.M. HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B 2005, 817, 67–76, doi:10.1016/j.jchromb.2004.07.045.
[23]
Bullinger, D.; Fr？hlich, H.; Klaus, F.; Neubauer, H.; Frickenschmidt, A.; Henneges, C.; Zell, A.; Laufer, S.; Gleiter, C.H.; Liebich, H.; Kammerer, B. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. Anal. Chim. Acta 2008, 618, 29–34, doi:10.1016/j.aca.2008.04.048.
[24]
Di Natale, C.; Macagnano, A.; Martinelli, E.; Paolesse, R.; D'Arcangelo, G.; Roscioni, C.; Finazzi-Agrò, A.; D’Amico, A. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens. Bioelectron. 2003, 18, 1209–1218, doi:10.1016/S0956-5663(03)00086-1.
[25]
Peng, G.; Hakim, M.; Broza, Y.Y.; Billan, S.; Abdah-Bortnyak, R.; Kuten, A.; Tisch, U.; Haick, H. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Brit. J. Cancer 2010, 103, 542–551, doi:10.1038/sj.bjc.6605810.
[26]
Hammett-Stabler, C.; Garg, U. The evolution of mass spectrometry in the clinical laboratory. Meth. Mol. Biol. 2010, 603, 1–7, doi:10.1007/978-1-60761-459-3_1.
[27]
Hakim, M.; Broza, Y.Y.; Barash, O.; Peled, N.; Phillips, M.; Amann, A.; Haick, H. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem. Rev. 2012, 112, 5949–5966, doi:10.1021/cr300174a.
[28]
Xu, H.; Wang, S. A novel sorptive extraction method based on polydimethylsiloxane frit for determination of lung cancer biomarkers in human serum. Anal. Chim. Acta 2012, 724, 61–66, doi:10.1016/j.aca.2012.02.046.
[29]
Rankin, K.S.; Starkey, M.; Lunec, J.; Gerrand, C.H.; Murphy, S.; Biswas, S. Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr. Blood Canc. 2012, 58, 327–333, doi:10.1002/pbc.23341.
[30]
Bentley, R.T.; Mund, J.A.; Pollok, K.E.; Childress, M.O.; Case, J. Peripheral blood biomarkers of solid tumor angiogenesis in dogs: A polychromatic flow cytometry pilot study. Vet. J. 2012. in press.
[31]
Uva, P.; Aurisicchio, L.; Watters, J.; Loboda, A.; Kulkarni, A.; Castle, J.; Palombo, F.; Viti, V.; Mesiti, G.; Zappulli, V.; et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 2009, 10, doi:10.1186/1471-2164-10-135.
[32]
Selvarajah, G.T.; Kirpensteijn, J. Prognostic and predictive biomarkers of canine osteosarcoma. Vet. J. 2010, 185, 28–35, doi:10.1016/j.tvjl.2010.04.010.
[33]
Requirements for the Collection, Processing and Quality Control of Blood, Blood Components and Plasma Derivatives; WHO Technical Report Series, No 840. Available online: http://www.who.int/bloodproducts/publications/WHO_TRS_840_A2.pdf (accessed on 8 December 2012).
[34]
Lin, J.-H.; Chou, M.-S. Henry’s law constant variations of volatile organic compounds in wastewater and activated sludge. Aerosol Air Qual. Res. 2006, 6, 180–192.
[35]
Brugnone, F.; De Rosa, E.; Perbellini, L.; Bartolucci, G.B. Toluene concentrations in the blood and alveolar air of workers during the workshift and the morning after. Brit. J. Ind. Med. 1986, 43, 56–61.
Brugnone, F.; Perbellini, L.; Wang, G.Z.; Maranelli, G.; Raineri, E.; De Rosa, E.; Saletti, C.; Soave, C.; Romeo, L. Blood styrene concentrations in a “normal” population and in exposed workers 16 hours after the end of the workshift. Int. Arch. Occup. Environ. Health 1993, 65, 125–130, doi:10.1007/BF00405731.
[38]
Knudsen, J.T.; Eriksson, R.; Gershenzon, J.; St？hl, B. Diversity and distribution of floral scent. Bot. Rev. 2006, 72, 1–120, doi:10.1663/0006-8101(2006)72[1:DADOFS]2.0.CO;2.
[39]
Chitarra, G.S.; Abee, T.; Rombouts, F.M.; Dijksterhuis, J. 1-Octen-3-ol inhibits conidia germination of Penicillium paneum despite of mild effects on membrane permeability, respiration, intracellular pH, and changes the protein composition. FEMS Microbiol. Ecol. 2005, 54, 67–75, doi:10.1016/j.femsec.2005.02.013.
[40]
McGinty, D.; Scognamiglio, J.; Letizia, C.S.; Api, A.M. Fragrance material review on 2-ethyl-1-hexanol. Food Chem. Toxicol. 2010, 48, S115–S129, doi:10.1016/j.fct.2010.05.042.
[41]
Jackson, J.A.; Riordan, H.D.; Neathery, S.; Riordan, N.H. Urinary pyrrole in health and disease. J. Orthomol. Med. 1997, 12, 96–98.
[42]
Schmutzhard, J.; Rieder, J.; Deibl, M.; Schwentner, I.M.; Schmid, S.; Lirk, P.; Abraham, I.; Gunkel, A.R. Pilot study: Volatile organic compounds as a diagnostic marker for head and neck tumors. Head Neck 2008, 30, 743–749, doi:10.1002/hed.20779.
[43]
Li, N.; Deng, C.; Yin, X.; Yao, N.; Shen, X.; Zhang, X. Gas chromatography-mass spectrometric analysis of hexanal and heptanal in human blood by headspace single-drop microextraction with droplet derivatization. Anal. Biochem. 2005, 342, 318–326, doi:10.1016/j.ab.2005.04.024.
[44]
Poli, D.; Carbognani, P.; Corradi, M.; Goldoni, M.; Acampa, O.; Balbi, B.; Bianchi, L.; Rusca, M.; Mutti, A. Exhaled volatile organic compounds in patients with non-small cell lung cancer: Cross sectional and nested short-term follow-up study. Respir. Res. 2005, 6, doi:10.1186/1465-9921-6-71.
[45]
Brunner, C.; Szymczak, W.; H？llriegl, V.; M？rtl, S.; Oelmez, H.; Bergner, A.; Huber, R.M.; Hoeschen, C.; Oeh, U. Discrimination of cancerous and non-cancerous cell lines by headspace-analysis with PTR-MS. Anal. Bioanal. Chem. 2010, 397, 2315–2324, doi:10.1007/s00216-010-3838-x.
